Camidanlumab Tesirine for the Treatment of R/R Hodgkin Lymphoma
Alex F. Herrera, MD, discusses the use of the antibody-drug conjugate, camidanlumab tesirine for the treatment of relapsed or refractory Hodgkin lymphoma.
Alex F. Herrera, MD, a hematologist/oncologist at the City of Hope Cancer Center, discusses the use of the antibody-drug conjugate, camidanlumab tesirine for the treatment of relapsed/ refractory (R/R) Hodgkin lymphoma (HL).
There are many treatment options available for patients living with R/R HL. Drugs like rituximab (Rituxan), nivolumab (Opdivo), and pembrolizumab (Keytruda) have greatly improved survival rates for patients. But, according to Herrera, very few options remain for patients whose tumors are resistant to these drugs.
For patients who cannot be cured through these conventional means, treatment options are desperately needed. Camidanlumab tesirine works by binding CD25 and delivers chemotherapy to the cancer cell.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Later-Line CD19 and Bispecific Therapies Considered After CAR T
October 1st 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.
Read More
Participants Discuss LOTIS-2 Data Based on Patient Case of DLBCL
September 16th 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed the data behind loncastuximab and whether participants with use this treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma
September 11th 2024The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.
Read More
